Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits

V De Francesco; A Zullo; E Ierardi; F Giorgio; Francesco Perna; Cesare Hassan; S Morini; C Panella; D. Vaira

doi:10.1093/jac/dkp445

Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits

V De Francesco, A Zullo, E Ierardi, F Giorgio, Francesco Perna, Cesare Hassan, S Morini, C Panella, D. Vaira

Risultato della ricerca: Contributo in rivista › Articolo in rivista

78 Citazioni (Scopus)

Abstract

Primary clarithromycin resistance is increasing worldwide, and it has been regarded as the main factor reducing the efficacy of Helicobacter pylori therapy. However, the clinical consequence of either phenotypic or genotypic resistance still remains unclear. This study aimed to evaluate: (i) the concordance between phenotypic (culture) and genotypic (real-time PCR) tests in assessing primary clarithromycin resistance; and (ii) the role of both in therapeutic outcome.

Lingua originale	English
pagine (da-a)	327-332
Numero di pagine	6
Rivista	Journal of Antimicrobial Chemotherapy
Volume	65
DOI	https://doi.org/10.1093/jac/dkp445
Stato di pubblicazione	Pubblicato - 2010
Pubblicato esternamente	Sì

Keywords

Adult
Anti-Bacterial Agents
Breath Tests
Clarithromycin
DNA, Bacterial
DNA, Ribosomal
Drug Resistance, Bacterial
Female
Gastric Mucosa
Helicobacter Infections
Helicobacter pylori
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Point Mutation
Polymerase Chain Reaction
RNA, Ribosomal, 23S
Treatment Outcome
Urease

Accesso al documento

10.1093/jac/dkp445

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{58d1ae07b908471db18dfd2840fb99fb,

title = "Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits",

abstract = "Primary clarithromycin resistance is increasing worldwide, and it has been regarded as the main factor reducing the efficacy of Helicobacter pylori therapy. However, the clinical consequence of either phenotypic or genotypic resistance still remains unclear. This study aimed to evaluate: (i) the concordance between phenotypic (culture) and genotypic (real-time PCR) tests in assessing primary clarithromycin resistance; and (ii) the role of both in therapeutic outcome.",

keywords = "Adult, Anti-Bacterial Agents, Breath Tests, Clarithromycin, DNA, Bacterial, DNA, Ribosomal, Drug Resistance, Bacterial, Female, Gastric Mucosa, Helicobacter Infections, Helicobacter pylori, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Point Mutation, Polymerase Chain Reaction, RNA, Ribosomal, 23S, Treatment Outcome, Urease, Adult, Anti-Bacterial Agents, Breath Tests, Clarithromycin, DNA, Bacterial, DNA, Ribosomal, Drug Resistance, Bacterial, Female, Gastric Mucosa, Helicobacter Infections, Helicobacter pylori, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Point Mutation, Polymerase Chain Reaction, RNA, Ribosomal, 23S, Treatment Outcome, Urease",

author = "{De Francesco}, V and A Zullo and E Ierardi and F Giorgio and Francesco Perna and Cesare Hassan and S Morini and C Panella and D. Vaira",

year = "2010",

doi = "10.1093/jac/dkp445",

language = "English",

volume = "65",

pages = "327--332",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press:Journals Department, Great Clarendon Street, Oxford OX2 6DP United Kingdom:011 44 1865 556767, EMAIL: [email protected], INTERNET: http://www.oup.co.uk, Fax: 011 44 1865 267485",

}

TY - JOUR

T1 - Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits

AU - De Francesco, V

AU - Zullo, A

AU - Ierardi, E

AU - Giorgio, F

AU - Perna, Francesco

AU - Hassan, Cesare

AU - Morini, S

AU - Panella, C

AU - Vaira, D.

PY - 2010

Y1 - 2010

N2 - Primary clarithromycin resistance is increasing worldwide, and it has been regarded as the main factor reducing the efficacy of Helicobacter pylori therapy. However, the clinical consequence of either phenotypic or genotypic resistance still remains unclear. This study aimed to evaluate: (i) the concordance between phenotypic (culture) and genotypic (real-time PCR) tests in assessing primary clarithromycin resistance; and (ii) the role of both in therapeutic outcome.

AB - Primary clarithromycin resistance is increasing worldwide, and it has been regarded as the main factor reducing the efficacy of Helicobacter pylori therapy. However, the clinical consequence of either phenotypic or genotypic resistance still remains unclear. This study aimed to evaluate: (i) the concordance between phenotypic (culture) and genotypic (real-time PCR) tests in assessing primary clarithromycin resistance; and (ii) the role of both in therapeutic outcome.

KW - Adult

KW - Anti-Bacterial Agents

KW - Breath Tests

KW - Clarithromycin

KW - DNA, Bacterial

KW - DNA, Ribosomal

KW - Drug Resistance, Bacterial

KW - Female

KW - Gastric Mucosa

KW - Helicobacter Infections

KW - Helicobacter pylori

KW - Humans

KW - Male

KW - Microbial Sensitivity Tests

KW - Middle Aged

KW - Point Mutation

KW - Polymerase Chain Reaction

KW - RNA, Ribosomal, 23S

KW - Treatment Outcome

KW - Urease

KW - Adult

KW - Anti-Bacterial Agents

KW - Breath Tests

KW - Clarithromycin

KW - DNA, Bacterial

KW - DNA, Ribosomal

KW - Drug Resistance, Bacterial

KW - Female

KW - Gastric Mucosa

KW - Helicobacter Infections

KW - Helicobacter pylori

KW - Humans

KW - Male

KW - Microbial Sensitivity Tests

KW - Middle Aged

KW - Point Mutation

KW - Polymerase Chain Reaction

KW - RNA, Ribosomal, 23S

KW - Treatment Outcome

KW - Urease

UR - http://hdl.handle.net/10807/34999

U2 - 10.1093/jac/dkp445

DO - 10.1093/jac/dkp445

M3 - Article

SN - 0305-7453

VL - 65

SP - 327

EP - 332

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

ER -

Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo